News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
383,234 Results
Type
Article (25707)
Company Profile (314)
Press Release (357213)
Section
Business (114097)
Career Advice (1644)
Deals (18489)
Drug Delivery (61)
Drug Development (64835)
Employer Resources (97)
FDA (13986)
Job Trends (8279)
News (213712)
Policy (23321)
Tag
Academia (1413)
Alliances (27173)
Alzheimer's disease (1048)
Approvals (13953)
Artificial intelligence (93)
Bankruptcy (175)
Best Places to Work (6987)
Biotechnology (252)
Breast cancer (140)
Cancer (1092)
Cardiovascular disease (84)
Career advice (1386)
CAR-T (82)
Cell therapy (244)
Clinical research (51921)
Collaboration (352)
Compensation (148)
COVID-19 (1923)
C-suite (88)
Cystic fibrosis (77)
Data (1165)
Diabetes (125)
Diagnostics (2630)
Earnings (48365)
Employer resources (84)
Events (57234)
Executive appointments (289)
FDA (14656)
Funding (342)
Gene therapy (188)
GLP-1 (437)
Government (3226)
Healthcare (10522)
Infectious disease (1987)
Inflammatory bowel disease (111)
Interviews (348)
IPO (10054)
Job creations (1640)
Job search strategy (1158)
Layoffs (299)
Legal (3290)
Lung cancer (163)
Manufacturing (124)
Medical device (5998)
Medtech (6001)
Mergers & acquisitions (8579)
Metabolic disorders (333)
Neuroscience (1332)
NextGen Class of 2024 (3402)
Non-profit (1839)
Northern California (1297)
Obesity (175)
Opinion (166)
Parkinson's disease (87)
Patents (80)
People (32706)
Phase I (16852)
Phase II (23072)
Phase III (17097)
Pipeline (470)
Postmarket research (1557)
Preclinical (6814)
Radiopharmaceuticals (230)
Rare diseases (238)
Real estate (2350)
Regulatory (18165)
Research institute (1325)
Resumes & cover letters (241)
Southern California (1146)
Startups (2245)
United States (11049)
Vaccines (421)
Weight loss (109)
Date
Today (3)
Last 7 days (104)
Last 30 days (1230)
Last 365 days (25333)
2025 (63)
2024 (25883)
2023 (28798)
2022 (35788)
2021 (37450)
2020 (33961)
2019 (26014)
2018 (19794)
2017 (20097)
2016 (17654)
2015 (21042)
2014 (15453)
2013 (11544)
2012 (12209)
2011 (12583)
2010 (11760)
Location
Africa (458)
Asia (25082)
Australia (5627)
California (2938)
Canada (1062)
China (255)
Colorado (119)
Connecticut (129)
Europe (50549)
Florida (370)
Georgia (93)
Illinois (218)
Indiana (124)
Maryland (547)
Massachusetts (2301)
Michigan (89)
Minnesota (143)
New Jersey (895)
New York (813)
North Carolina (553)
Northern California (1297)
Ohio (100)
Pennsylvania (616)
South America (556)
Southern California (1146)
Texas (360)
Washington State (295)
383,234 Results for "australian therapeutic goods administration".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Application for the OTC-HOPE Phase 1/2 Study of ECUR-506
iECURE, Inc. announced today that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Clinical Trial Notification (CTN) for ECUR-506 (formerly GTP-506), an investigational therapy in development for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients.
December 13, 2023
·
7 min read
Press Releases
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington’s Disease Patient Trial
December 10, 2024
·
3 min read
Policy
Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
Venus Concept Inc., a global medical aesthetic technology leader, announced that it has Therapeutic Goods Administration clearance in Australia to market the Venus Versa Pro system.
April 3, 2024
·
3 min read
Career Advice
11 Signs of Good Company Culture
Good company culture is a crucial aspect of professional life. Look at these 11 important indications of good workplace culture before accepting a job offer or use them to evaluate your new employer.
September 19, 2024
·
4 min read
·
Editorial Staff
Policy
Neurophth Secures Australian Approval for Ophthalmic Gene Therapy
Neurophth Therapeutics, a leader in in-vivo gene therapy for ophthalmic diseases in China, announced the Australian Therapeutic Goods Administration has registered and approved its candidate drug, NFS-05, for clinical trials targeting Autosomal Dominant Optic Atrophy.
September 6, 2023
·
3 min read
Press Releases
Venus Concept Announces Australian Regulatory Approval for Venus Bliss MAX
September 18, 2024
·
3 min read
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced that 10 breast scaffold patients and 5 pectus patients have successfully passed one-year follow-up in BellaSeno´s Australian clinical trials.
June 12, 2024
·
3 min read
Immuron Presentation Australian Biologics Festival 2024
Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia.
February 21, 2024
·
1 min read
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
HaemaLogiX Ltd is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLogiX Board as a Non-Executive Director.
May 20, 2024
·
6 min read
Policy
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
FibroBiologics, Inc. announced the issuance of a patent from the Australian Patent Office covering the proprietary method using a particular cellular blend for the regeneration of chondrocytes or cartilage-type cells.
April 11, 2024
·
4 min read
1 of 38,324
Next
